chemotherapy. The (1990), 61, 345-346 of human cell lines and xenografts, together with reverse transformation, suppression of myc and ras proteins, and promotion of differentiation. These exciting analogues differ from older ones like dibutyryl cAMP, and the 8-chloro compound looks promising for clinical trial.
Felsted et al. discuss another means of sabotaging transforming proteins. Certain key proteins require acylation for location within the inner leaflet of the cell membrane. These include not only the viral gag-encoded proteins (including HIV) but also src and ras gene products, cAMP-dependent protein kinases, the transferrin receptor, cytoskeletal proteins ankyrin and vinculin, and the erythrocyte spectrin-actin cross-linking protein band 4.1. Mutations in src and ras which reduce acylation also inhibit transformation. The authors describe several possible wrecking sites and favour blockade of myristoyl/palmitoyl CoA synthesis and myristoyl/ palmitoyl transferases. It is too early to judge how selective this will be, but it is certainly an interesting approach.
In The scope of this book is wide, but not totally comprehensive. There is nothing here on sequence-selective DNA targeting, for example, and very little on ether lipids. This is a rapidly advancing field and the book is dating equally fast. One could quibble that the authors represent solely laboratories in the USA. Nevertheless, it will be valuable reading to those interested in new approaches to cancer chemotherapy. Presentational style is variable (e.g. emphasis on personal experimental data versus overview), but this is typical of multi-author monographs. The price will make the book a library purchase rather than an individual one. The publication quality is good, and I could find few typographical errors.
There are, happily, many philosophies of modern cancer chemotherapy. Most are valid. Some are more interesting than others. The main one to avoid is the ostrich philosophy. Rational design, exploitation of new biochemistry and technology, and sensible screening are paramount, with therapeutic selectivity always in mind. It needs good biology, chemistry and interdisciplinary collaboration, and this in turn must be energized by adequate funding. Maybe the last word should again be from A Tale of Two Cities: 'Although it's a long time on the road, it is on the road and coming. I tell thee it never retreats and never stops.' Let's hope it's not fin de siecle but a new millenium for cancer chemotherapy.
Paul Workman
